Andrew Seidman, MD, and Ruth O'Regan, MD: Update on Early Breast Cancer
2015 San Antonio Breast Cancer Symposium
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Ruth M. O’Regan, MD, of the University of Wisconsin, review practice-changing research in 2015 that was focused on early-stage breast cancer.
Judy E. Garber, MD, MPH
Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.
Clifford A. Hudis, MD, and Carlos L. Arteaga, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.
Andrew Seidman, MD, and Seema A. Khan, MD, MPH
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).
Andrew Seidman, MD, and Norman Wolmark, MD
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)
Harold J. Burstein, MD, PhD
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).